Neurology
Traumatic Brain Injury
3
Pipeline Programs↗
14
Active Trials↗
5
Companies Involved↗
Traumatic Brain Injury is an early-stage landscape with 3 programs across 5 companies. The most active players are Fresenius Kabi Oncology Ltd., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Mario Negri Institute for Pharmacological Research.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
18
clinical trials
Recruiting10 · 56%
Completed4 · 22%
Not yet recruiting4 · 22%
Clinical Trials
Trial Activity
18 trials
Assessment of Traumatic Brain Injury Using Transcranial Magnetic Stimulated Evoked Potentials (TMS-EEG)
Not yet recruiting·—·N/A·NCT06963775·215 enrolled
Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT01132937·886 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)